资料显示，福建万辰食品集团股份有限公司位于福建漳浦台湾农民创业园,香港铜锣湾希慎道33号利园1 期19楼1917室，成立日期2011年12月21日，上市日期2021年4月19日，公司主营业务涉及鲜品食用菌的 研发、工厂化培育与销售。主营业务收入构成为：零食产品98.95%，食用菌1.05%。 截至9月30日，万辰集团股东户数1.14万，较上期增加44.39%；人均流通股14573股，较上期减少 25.90%。2025年1月-9月，万辰集团实现营业收入365.62亿元，同比增长77.37%；归母净利润8.55亿元， 同比增长917.04%。 分红方面，万辰集团A股上市后累计派现1.70亿元。近三年，累计派现1.36亿元。 机构持仓方面，截止2025年9月30日，万辰集团十大流通股东中，香港中央结算有限公司位居第八大流 通股东，持股374.04万股，相比上期减少14.74万股。东方红启恒三年持有混合A（910004）位居第十大 流通股东，持股266.84万股，为新进股东。东方红启东三年持有混合（008985）退出十大流通股东之 列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点， ...

1月30日，万辰集团涨5.03%，截至发稿，报213.48元/股，成交1.27亿元，换手率0.36%，总市值403.25 亿元。 资料显示，福建万辰食品集团股份有限公司位于福建漳浦台湾农民创业园,香港铜锣湾希慎道33号利园1 期19楼1917室，成立日期2011年12月21日，上市日期2021年4月19日，公司主营业务涉及鲜品食用菌的 研发、工厂化培育与销售。主营业务收入构成为：零食产品98.95%，食用菌1.05%。 从基金十大重仓股角度 数据显示，中信建投基金旗下1只基金重仓万辰集团。中信建投远见回报A（011868）四季度持有股数 2.25万股，占基金净值比例为0.98%，位居第七大重仓股。根据测算，今日浮盈赚取约23.02万元。 截至发稿，谢玮累计任职时间7年242天，现任基金资产总规模16.42亿元，任职期间最佳基金回报 79.81%， 任职期间最差基金回报-31.63%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 ...

截至发稿，何文逸累计任职时间3年350天，现任基金资产总规模6.54亿元，任职期间最佳基金回报 32.76%， 任职期间最差基金回报-39.59%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 数据显示，中海基金旗下1只基金重仓万辰集团。中海消费混合A（398061）四季度减持1.24万股，持有 股数4.31万股，占基金净值比例为4.76%，位居第三大重仓股。根据测算，今日浮亏损失约48.83万元。 中海消费混合A（398061）成立日期2011年11月9日，最新规模1.81亿。近一年收益1.99%，同类排名 7793/8126；成立以来收益249.09%。 中海消费混合A（398061）基金经理为何文逸。 1月29日，万辰集团跌5.21%，截至发稿，报206.22元/股，成交1.35亿元，换手率0.38%，总市值389.53 亿元。 资料显示，福建万辰食品集团股份有限公司位于福建漳浦台湾农民创业园,香港铜锣 ...

Group 1 - The core point of the news is that Wancheng Group's stock has experienced a decline of 2.11% on January 14, with a cumulative drop of 8.99% over three consecutive days, leading to a market capitalization of 35.965 billion yuan [1] - Wancheng Group, established on December 21, 2011, and listed on April 19, 2021, is primarily engaged in the research, cultivation, and sales of fresh edible mushrooms, with 98.95% of its revenue coming from snack products and 1.05% from edible mushrooms [1] - The trading volume for Wancheng Group on January 14 was 473 million yuan, with a turnover rate of 1.47% [1] Group 2 - From the perspective of major fund holdings, Chuangjin Hexin Fund has a significant position in Wancheng Group, with its Chuangjin Hexin Consumer Theme Stock A (003190) holding 34,700 shares, representing 6.49% of the fund's net value, making it the largest holding [2] - The fund has incurred a floating loss of approximately 142,300 yuan today and a total floating loss of 652,700 yuan during the three-day decline [2] - Chuangjin Hexin Consumer Theme Stock A (003190) was established on August 22, 2016, with a current scale of 34.4847 million yuan, and has achieved a year-to-date return of 3.2% [2]

Core Viewpoint - The company plans to acquire a 49.00% stake in Nanjing Wanyou Commercial Management Co., Ltd. from Huainan Shengyu Enterprise Management Co., Ltd. and Huainan Huixiang Enterprise Management Co., Ltd. through a cash payment, which constitutes a major asset restructuring and related party transaction [1][2]. Group 1 - The transaction aims to strengthen the company's control over its subsidiary, enhance overall governance, and align with the company's long-term development strategy, thereby improving its competitive edge [2]. - The target company's main business is retail snack sales, which aligns with the company's primary business of retail snack sales and the research, cultivation, and sales of edible fungi, both classified under "F52 Retail" in the national economic industry classification [2]. - The transaction complies with the relevant provisions of the "Continuous Supervision Measures for GEM Listed Companies (Trial)" and the "Major Asset Restructuring Review Rules of the Shenzhen Stock Exchange" [1][2].

Group 1 - The company, Fujian Wancheng Biotechnology Group Co., Ltd., plans to acquire minority stakes in Nanjing Wanyou Commercial Management Co., Ltd. through cash payment, constituting a major asset restructuring [1][2] - The transaction aims to enhance the company's control over its subsidiaries, improve overall governance, and align with the company's long-term development strategy, thereby increasing its competitive strength [2] - The target company's main business is retail snack sales, which aligns with the company's primary business of retail snack sales and the research, cultivation, and sales of edible fungi, both classified under "F52 Retail" in the national economic industry classification [2]

Group 1 - The core point of the news is that Shanghai Xuerong Biotechnology Co., Ltd. plans to establish a new subsidiary, Chengdu Xuesao Biotechnology Co., Ltd., to focus on the artificial cultivation and commercialization of Cordyceps, a species of national secondary protected plant [1] - Chengdu Xuesao will have a registered capital of 20 million yuan, with Xuerong contributing 10.2 million yuan (51%), Chenshi Biotechnology contributing 7 million yuan (35%), and Zheng Weidong contributing 2.8 million yuan (14%) [1] - The establishment of this subsidiary aligns with the company's strategy for diversified product offerings and aims to enhance production capacity utilization while reducing costs in the existing edible fungus business [1] Group 2 - Xuerong Biotechnology primarily engages in the research, industrial cultivation, and sales of fresh edible fungi [2] - In the first quarter of 2025, the company reported a revenue of 441 million yuan, a year-on-year decrease of 27.04%, while the net profit attributable to shareholders increased by 38.20% to 7.24 million yuan [2]